Sugi Predict

Sugi Predict / Compounds / SCHEMBL165314

SCHEMBL165314

SCHEMBL165314

COc1ccccc1C(N)(OC)OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.50
▸ CA2 P00918 3/20 0.50
▸ CA7 P43166 2/20 0.50
▸ CA9 Q16790 2/20 0.50
▸ CA12 O43570 1/20 0.50
▸ CA4 P22748 1/20 0.50
▸ CA14 Q9ULX7 1/20 0.50
▸ ALDH1A1 P00352 5/20 0.46
▸ ADRA2B P18089 1/20 0.46
▸ PTGS1 P23219 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ TP53 P04637 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ APP P05067 1/20 0.41
▸ CASR P41180 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ IDO1 P14902 3/20 0.39
▸ TAAR1 Q96RJ0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2076078 0.98 CA1 (0.48) CA1CA2CA7CA9CA12
SCHEMBL31449927 0.82 SMN1; SMN2 (0.42) CA1CA2CA7CA9CA12
SCHEMBL4631777 0.80 CA1 (0.52) CA1CA2CA7CA9CA12
SCHEMBL18543499 0.78 CA1 (0.50) CA1CA2CA7CA9CA12
SCHEMBL5675558 0.77 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL3671684 0.77 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL8784754 0.77 CA1 (0.55) CA1CA2CA7CA9CA12
SCHEMBL3978964 0.77 CA1 (0.48) CA1CA2CA7CA9CA12
SCHEMBL3205223 0.77 CASR (0.50) CA1CA2CA7CA9CA12
SCHEMBL7608708 0.77 CA1 (0.48) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6444662-B1 REACTION WITH AMINE BASE WILLMAR SCHWABE GMBH & CO. (DE) 2002-09-03 — — US claimed
CN-119799806-A Preparation process for efficiently producing gallic acid 广州卫生职业技术学院 2025-04-11 — — CN disclosed
CN-118290241-A Application of naringin and method for preparing natural p-hydroxybenzaldehyde by naringin 陕西嘉禾生物科技股份有限公司 2024-07-05 — — CN disclosed
CN-116606824-B Isoeugenol monooxygenase mutant IEM-F305W-L470E, engineering bacteria and application 山东中酶生物科技有限公司 2023-09-26 — — CN disclosed
CN-116478942-B Isoeugenol monooxygenase mutant, engineering bacteria and application 山东中酶生物科技有限公司 2023-09-08 — — CN disclosed
CN-116606824-A Isoeugenol monooxygenase mutant IEM-F305W-L470E, engineering bacteria and application 山东中酶生物科技有限公司 2023-08-18 — — CN disclosed
CN-116478942-A Isoeugenol monooxygenase mutant, engineering bacteria and application 山东中酶生物科技有限公司 2023-07-25 — — CN disclosed
CN-114306613-A Pharmaceutical composition 查尔斯顿实验室公司 2022-04-12 — — CN disclosed
CN-106957314-B Pyrimidine derivatives as RAF kinase inhibitors 苏尼西斯制药有限公司 2019-12-31 — — CN disclosed
EP-3231798-B1 THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS INC (US) 2019-10-09 — — EP disclosed
US-20050019825-A9 Common ligand mimics: pseudothiohydantoins TRIAD THERAPEUTICS, INC. 2005-01-27 — — US disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 — — US disclosed
US-20040024203-A1 Benzodiazepine derivatives as inhibitors of gamma secretase MERCK SHARP & DOHME LTD. (GB) 2004-02-05 — — US disclosed
EP-1326849-A1 BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE Merck Sharp & Dohme Limited (GB) 2003-07-16 — — EP disclosed
EP-1294702-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LTD. (GB) 2003-03-26 — — EP disclosed
WO-2002030912-A1 BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE MERCK SHARP & DOHME LIMITED (GB) 2002-04-18 — — WO disclosed
WO-2001090084-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 — — WO disclosed
EP-1091928-A1 NOVEL ACYL PSEUDODIPEPTIDES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME OM Pharma (CH) 2001-04-18 — — EP disclosed
WO-2000000462-A1 NOVEL ACYL PSEUDODIPEPTIDES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME OM PHARMA (CH) 2000-01-06 — — WO disclosed
EP-0801083-A2 Improved functionalized resin for chemical synthesis PFIZER INC. (US) 1997-10-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050019825-A9 Common ligand mimics: pseudothiohydantoins FGFR3, BID, FLT3 CA1 2419/4885CA2 2096/4885CA7 1842/4885
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP CA1 1551/4885CA2 3928/4885CA7 4814/4885
US-20040024203-A1 Benzodiazepine derivatives as inhibitors of gamma secretase BACE1, BACE2, PSEN1 CA1 429/4885CA2 2296/4885CA7 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.